During a characteristically bizarre and rambling press conference, Donald Trump yesterday fought back against lurid reports from Russia, but two policies nevertheless emerged as priorities:
The US Congress may pass the 21 Century Cures Act this week, a major new piece of legislation affecting healthcare, the FDA and pharma - but the battle for what measures will be included an
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh